Paramune

Executive Summary

Paramune is a San Diego-based private biotech company founded in 2020, focused on harnessing novel molecular mechanisms to develop next-generation biologics for cancer and autoimmune diseases. By leveraging fundamental discoveries in disease pathology, the company engineers therapeutic candidates including monoclonal antibodies, bispecifics, engagers, and antibody cocktails to precisely engage identified targets. Paramune is currently in Phase 1 clinical development, aiming to validate its platform in humans. The company’s approach addresses key limitations of existing therapies, potentially offering improved efficacy and safety profiles. Despite being in early stages, Paramune’s scientific foundation and focus on innovative biologic formats position it as a promising player in the biotherapeutics space.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1 data readout for lead candidate40% success
• Q2 2027Partnership or licensing deal with larger pharma30% success
• Q1 2027Series B financing round to support pipeline expansion60% success